Future Directions in Maintenance Therapy in Multiple Myeloma

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Background:

• Autologous stem cell transplantation (ASCT) is a cornerstone treatment for multiple myeloma.
• Survival rates have improved due to effective induction and maintenance therapies.
• Lenalidomide maintenance is a current standard of care post-ASCT.

Purpose of the Study:

• To review current evidence on novel post-ASCT maintenance strategies for multiple myeloma.
• To explore the role of immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies.
• To discuss future directions and unresolved questions in multiple myeloma maintenance therapy.

Main Methods:

• Literature review of randomized phase III clinical trials.
• Synthesis of evidence on various post-ASCT maintenance regimens.
• Discussion of emerging therapeutic approaches.

Main Results:

• Lenalidomide maintenance is established as standard care.
• Ongoing research focuses on alternative and combination maintenance strategies.
• Significant interest exists in improving upon current lenalidomide maintenance protocols.

Conclusions:

• Despite advances, multiple myeloma relapse remains a challenge post-ASCT.
• Novel maintenance therapies are essential to further enhance long-term survival.
• Further research is needed to optimize post-ASCT maintenance strategies.